BioMarin Pharmaceutical Inc.
BMRN
$58.14
$0.290.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 745.15M | 747.31M | 745.74M | 712.03M | 648.83M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 745.15M | 747.31M | 745.74M | 712.03M | 648.83M |
| Cost of Revenue | 310.29M | 136.14M | 188.46M | 314.25M | 330.17M |
| Gross Profit | 434.86M | 611.17M | 557.28M | 397.78M | 318.67M |
| SG&A Expenses | 206.12M | 170.78M | 253.48M | 224.01M | 225.91M |
| Depreciation & Amortization | 4.85M | 9.65M | 5.01M | 14.30M | 14.30M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 521.25M | 490.08M | 631.85M | 552.55M | 570.37M |
| Operating Income | 223.89M | 257.24M | 113.89M | 159.48M | 78.46M |
| Income Before Tax | 238.09M | 169.64M | 134.44M | 132.14M | 105.55M |
| Income Tax Expenses | 52.40M | 44.70M | 28.36M | 24.96M | 16.89M |
| Earnings from Continuing Operations | 185.69M | 124.94M | 106.08M | 107.17M | 88.66M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 185.69M | 124.94M | 106.08M | 107.17M | 88.66M |
| EBIT | 223.89M | 257.24M | 113.89M | 159.48M | 78.46M |
| EBITDA | 245.96M | 280.84M | 132.90M | 185.94M | 105.81M |
| EPS Basic | 0.97 | 0.66 | 0.56 | 0.56 | 0.47 |
| Normalized Basic EPS | 0.78 | 0.87 | 0.44 | 0.56 | 0.32 |
| EPS Diluted | 0.95 | 0.64 | 0.55 | 0.55 | 0.46 |
| Normalized Diluted EPS | 0.76 | 0.84 | 0.43 | 0.53 | 0.30 |
| Average Basic Shares Outstanding | 190.97M | 190.69M | 190.43M | 190.11M | 188.87M |
| Average Diluted Shares Outstanding | 196.47M | 196.58M | 197.15M | 200.51M | 199.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |